{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:57:47Z","timestamp":1790647067547,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T00:00:00Z","timestamp":1488412800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00296-017-3687-4","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T08:02:54Z","timestamp":1488441774000},"page":"1381-1385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Etanercept-induced leukemia: could increased mean corpuscular volume be a predictor of hematologic malignancy?"],"prefix":"10.1007","volume":"37","author":[{"given":"D\u00f6nd\u00fc \u00dcsk\u00fcdar","family":"Cansu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hava \u00dcsk\u00fcdar","family":"Teke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"key":"3687_CR1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.18433\/J3WP4F","volume":"17","author":"RM Nanau","year":"2014","unstructured":"Nanau RM, Neuman MG (2014) Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci 17:324\u2013361","journal-title":"J Pharm Pharm Sci"},{"key":"3687_CR2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/keg128","volume":"42","author":"G Bakland","year":"2003","unstructured":"Bakland G, Nossent H (2003) Acute myelogenous leukaemia following etanercept therapy. Rheumatology (Oxford) 42:900\u2013901","journal-title":"Rheumatology (Oxford)"},{"key":"3687_CR3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaad.2006.06.032","volume":"56","author":"C Bachmeyer","year":"2007","unstructured":"Bachmeyer C, Thioli\u00e8re B, Khosrotehrani K, Cattan E (2007) Acute myelogenous leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 56:169\u2013170","journal-title":"J Am Acad Dermatol"},{"key":"3687_CR4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/ajh.20926","volume":"82","author":"B Nair","year":"2007","unstructured":"Nair B, Raval G, Mehta P (2007) TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 82:1022\u20131024","journal-title":"Am J Hematol"},{"key":"3687_CR5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2010.06.049","volume":"65","author":"RM Knudson","year":"2011","unstructured":"Knudson RM, Tefferi A, Pittelkow MR, Davis MD (2011) Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol 65:673\u2013674","journal-title":"J Am Acad Dermatol"},{"key":"3687_CR6","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.jaad.2012.03.037","volume":"67","author":"M Sadlier","year":"2012","unstructured":"Sadlier M, Connaghan G, Kirby B (2012) Acute myeloid leukemia presenting with cutaneous infiltrates in a patient receiving etanercept for chronic lymphocytic vasculitis. J Am Acad Dermatol 67:e264\u2013e265","journal-title":"J Am Acad Dermatol"},{"key":"3687_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/11599850-000000000-00000","volume":"32","author":"F Ferrer-Mar\u00edn","year":"2012","unstructured":"Ferrer-Mar\u00edn F, Amigo ML, Vicente V (2012) Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors. Clin Drug Investig 32:423\u2013426","journal-title":"Clin Drug Investig"},{"key":"3687_CR8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ibd.21005","volume":"16","author":"M Cesarini","year":"2010","unstructured":"Cesarini M, Vernia P, Angelucci E (2010) Acute lymphoid leukemia in a Crohn\u2019s disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids. Inflamm Bowel Dis 16:371\u2013372","journal-title":"Inflamm Bowel Dis"},{"key":"3687_CR9","first-page":"999","volume":"27","author":"F Kemta Lekpa","year":"2009","unstructured":"Kemta Lekpa F, Zahra K, Pautas C, Maury S, Chevalier X, Claudepierre P (2009) Acute myeloid leukemia after infliximab: a case report. Clin Exp Rheumatol 27:999\u20131000","journal-title":"Clin Exp Rheumatol"},{"key":"3687_CR10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s12185-016-2043-x","volume":"104","author":"N Takahashi","year":"2016","unstructured":"Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R et al (2016) Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol 104:344\u2013357","journal-title":"Int J Hematol"},{"key":"3687_CR11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2141.2002.03783.x","volume":"119","author":"GB Tennant","year":"2002","unstructured":"Tennant GB, Al-Sabah AI, Burnett AK (2002) Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol 119:87\u201396","journal-title":"Br J Haematol"},{"key":"3687_CR12","doi-asserted-by":"crossref","unstructured":"Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon W et al (2017) Risk of lymphoma in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis\u00a076:497\u2013503","DOI":"10.1136\/annrheumdis-2016-209389"},{"key":"3687_CR13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","volume":"26","author":"M Harigai","year":"2016","unstructured":"Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y et al (2016) Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan. Mod Rheumatol 26:642\u2013650","journal-title":"Mod Rheumatol"},{"key":"3687_CR14","doi-asserted-by":"crossref","first-page":"32063","DOI":"10.1038\/srep32063","volume":"6","author":"C Deng","year":"2016","unstructured":"Deng C, Li W, Fei Y, Li Y, Zhang F (2016) Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep 6:32063","journal-title":"Sci Rep"},{"key":"3687_CR15","doi-asserted-by":"crossref","unstructured":"Hellgren K, Dreyer L, Arkema EV, Glintborg B, Jacobsson LT, Kristensen L et al (2017) Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis\u00a076:105\u2013111","DOI":"10.1136\/annrheumdis-2016-209270"},{"key":"3687_CR16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14737140.2.3.277","volume":"2","author":"AM Tsimberidou","year":"2002","unstructured":"Tsimberidou AM, Giles FJ (2002) TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther 2:277\u2013286","journal-title":"Expert Rev Anticancer Ther"},{"key":"3687_CR17","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","volume":"29","author":"X Wang","year":"2008","unstructured":"Wang X, Lin Y (2008) Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 29:1275\u20131288","journal-title":"Acta Pharmacol Sin"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-017-3687-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T13:39:01Z","timestamp":1500989941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-017-3687-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3687"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3687-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}